Previous Close | 3.1000 |
Open | 3.1000 |
Bid | 2.7700 x 800 |
Ask | 3.0000 x 800 |
Day's Range | 2.9100 - 3.1500 |
52 Week Range | 2.6500 - 7.3800 |
Volume | |
Avg. Volume | 37,725 |
Market Cap | 37.528M |
Beta (5Y Monthly) | -0.51 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.2800 |
Earnings Date | Apr 14, 2022 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 13.00 |
RALEIGH, NC / ACCESSWIRE / May 16, 2022 / The Spring into Action- Best Ideas Virtual Investor Conference will take place on May 16th \- 20th, 2022, where 36 SmallCap, MicroCap and NanoCap public companies will be presenting via virtual webcast to a global investor audience.The Spring into Action: VIRTUAL begins on Monday, May 16th, 2022, with a Biotech Discovery Day.
- Attaining CE Mark is a major step toward commercialization – - World Health Organization (WHO) lists H. pylori among the 16 antibiotic-resistant bacteria that pose the greatest threat to human health and designated H. pylori as a Class 1 carcinogen, meaning that it is a known cause of cancer - - 45% of the population in Europe’s five largest countries are afflicted with H. pylori - IRVINE, Calif., May 12, 2022 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), (the “Company”) a global provide
Gastric cancer is the third most common cause of cancer related death in the world and over 80% of gastric cancers are attributed to H. pylori bacterial infection H. pylori infection is also a major cause of peptic ulcers IRVINE, Calif., April 26, 2022 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), (the “Company”) a global provider of advanced medical diagnostic and therapeutic products, today announced it has submitted a 510(k) premarket notification to the U.S. Food and Drug Administratio